| Hypofractionated stereotactic radiotherapy (hfSRT) after tumour resection of a single brain metastasis: report of a single-centre individualized treatment approach. | |
| | |
MedLine Citation:
|
PMID: 22526164 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: Standard treatment of single brain metastases so far is tumour resection in combination with postoperative whole-brain radiotherapy or stereotactic radiosurgery. Here, we report retrospectively our first experience with postoperative hypofractionated stereotactic radiotherapy (hfSRT) to the resection cavity in order to replace upfront WBRT with respect to treatment efficacy and safety. METHODS: Between March 2006 and October 2011, 33 patients with a single newly diagnosed intracranial metastasis were treated with hfSRT following microsurgical resection. Fractionation concepts were 10 × 4 Gy (n = 22), 7 × 5 Gy (n = 7) and 5 × 6 Gy (n = 4). Planning target volume enclosed the tumour resection cavity with a safety margin of 4 mm. RESULTS: No patient demonstrated toxicity grade 2 or higher. Actuarial median overall survival summed up to 20.2 months, and 12-month survival was 64 %. Actuarial mean local brain control was 30.6 months, median distant brain control 12.4 months and intracranial control 8.8 months, respectively. Actuarial 1-year rates of local, distant brain and intracranial control were 71, 57 and 43 %. Salvage whole-brain radiotherapy due to recurrent brain metastases was performed in 13 patients (39 %). CONCLUSION: Postoperative hfSRT appears to be a feasible treatment option in patients with a single newly diagnosed brain metastasis. Replacing the standard postoperative whole-brain radiotherapy necessitates compliant patients and regular MRI follow-up analysis. |
| | |
Authors:
|
Diana Steinmann; Bettina Maertens; Stefan Janssen; Martin Werner; Jörg Frühauf; Makoto Nakamura; Hans Christiansen; Michael Bremer |
Related Documents
:
|
17066234 - Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced mel... 22619474 - Sylatron: a pegylated interferon for use in melanoma (june). 22372544 - Therapy innovation for the treatment of pancreatic neuroendocrine tumors. 22782964 - Management of ureteral obstruction in advanced testicular tumor with lymph node metasta... 17307024 - A decision analysis: the dental management of patients prior to hematology cytotoxic th... 1142954 - Laryngeal structure following microcauterization. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-24 |
Journal Detail:
|
Title: Journal of cancer research and clinical oncology Volume: - ISSN: 1432-1335 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7902060 Medline TA: J Cancer Res Clin Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Radiation Oncology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany, steinmann.diana@mh-hannover.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of the functional MKK4 promoter variant (-1304T>G) in a decreased risk of prostate cancer: case...
Next Document: Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of...